Table 5.
Univariate analysis of recurrence free survival in all 171 patients (log-rank test)
| n | 1-year | 3-year | 5-year | 10-year | p-value† | |
| Age (in years) | 0.02† | |||||
| ≤ 53 | 88 | 73.8 (56) | 55.9 (34) | 44.9 (20) | 37 (1) | |
| > 53 | 83 | 88.7 (65) | 68.4 (31) | 62.4 (19) | 55.5 (2) | |
| Sex | 0.09 | |||||
| Female | 71 | 77.8 (47) | 55 (25) | 47.2 (15) | 39.5 (2) | |
| Male | 100 | 83.2 (74) | 67.5 (40) | 57.2 (24) | 48 (1) | |
| Race | 0.27 | |||||
| Caucasian | 140 | 83 (102) | 63.8 (54) | 55.4 (33) | 48.3 (3) | |
| non-Caucasian | 31 | 72.1 (19) | 54.7 (11) | 42.2 (6) | 21.1 (0) | |
| PTT | < 0.001† | |||||
| Carcinoma | 87 | 94 (76) | 77.4 (45) | 65.4 (28) | 59.1 (2) | |
| Sarcoma | 84 | 67.2 (45) | 44.5 (20) | 39.7 (11) | 28.3 (1) | |
| DFI-1 | 0.79 | |||||
| < 1 years | 34 | 84.9 (22) | 58.2 (10) | 58.2 (10) | 58.2 (1) | |
| 1 to 5 years | 92 | 76.3 (62) | 63 (37) | 52.8 (20) | 42.7 (1) | |
| > 5 years | 45 | 88.4 (37) | 62.8 (18) | 49.4 (9) | 35.1 (1) | |
| Laterality | 0.03† | |||||
| Unilateral | 124 | 85.1 (96) | 65.8 (51) | 59.8 (31) | 47.6 (1) | |
| Bilateral | 47 | 69.3 (25) | 51.2 (14) | 34.9 (8) | 34.9 (2) | |
| Magnitude | 0.02† | |||||
| Wedge | 118 | 77.9 (80) | 55.8 (42) | 46.1 (28) | 40 (2) | |
| All other | 53 | 87.9 (41) | 76.7 (23) | 76.7 (11) | 54.8 (1) | |
| Number of lesions | 0.05 | |||||
| Single | 48 | 91.4 (40) | 69.3 (23) | 62.7 (16) | 51.2 (0) | |
| 2–5 | 94 | 77.9 (65) | 64.6 (34) | 55.6 (19) | 47.3 (3) | |
| > 5 | 29 | 72.9 (16) | 40.1 (8) | 27.5 (4) | 27.5 (0) | |
| Neoadjuvant | 0.63 | |||||
| No | 99 | 78.4 (66) | 62.2 (37) | 51.6 (22) | 41.3 (1) | |
| Yes | 72 | 84.4 (55) | 62.2 (28) | 55 (17) | 49.5 (2) | |
| Procedure | 0.27 | |||||
| OPEN | 135 | 78.9 (92) | 60.9 (55) | 50.5 (33) | 41.5 (3) | |
| VATS | 36 | 88.5 (29) | 66.5 (10) | 66.5 (6) | 66.5 (0) | |
*All survival rates are expressed as % (number at risk), unless specified otherwise.
† Two-tailed p-value < 0.05 considered statistically significant.